Lundbeck expands its commercial opportunities in Canada and Latin America
H. Lundbeck A/S announced that Lundbeck has been granted commercial rights to several Cephalon products in Canada and Latin America. As part of the agreement, Lundbeck will register and commercialise several key products which are currently available in the US and/or Europe on behalf of Cephalon. Key products in the agreement include Fentora® (fentanyl buccal tablet) [C-II], Provigil®, Treanda®, Trisenox® (arsenic trioxide) injection, Myocet® (liposomal- doxorubicin) and Nuvigil®.
"The Cephalon brands will significantly strengthen our position in these markets while leveraging on existing sales and marketing capabilities adding significant sales in Canada and Latin America from 2012," says Ulf Wiinberg, President & Chief Executive Officer at Lundbeck. "It is our belief that the clinical and regulatory risk is minimal as these products are already approved in the US and some of the products also in Europe."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
